← brief for 2026-08-16 · Slowing decline

Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection.

Article No results yet Peer reviewed

Key takeaways

This is a review of two diabetes drug types, GLP-1 medicines and SGLT2 inhibitors, that also protect the heart and kidneys. It explains how they may lower inflammation and improve blood flow. A review pulls together past work, so it offers no new trial results of its own.

Who did this work

Mohanty SS · Selvammathy RR · Ahad HA · Kumar ES

Source

Article · PubMed, the drug frontier · 2026 Jul 1
https://pubmed.ncbi.nlm.nih.gov/42583965/